Search

Your search keyword '"Harvey, Ruth"' showing total 451 results

Search Constraints

Start Over You searched for: Author "Harvey, Ruth" Remove constraint Author: "Harvey, Ruth"
451 results on '"Harvey, Ruth"'

Search Results

1. Antigenic drift and subtype interference shape A(H3N2) epidemic dynamics in the United States.

4. Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: a mathematical modelling study

5. Immersion

7. Reviews

13. Strong peak immunogenicity but rapid antibody waning following third vaccine dose in older residents of care homes

14. Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: A nested case-control within the SIREN study

15. Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility

17. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study

18. Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study

19. Favorable antibody responses to human coronaviruses in children and adolescents with autoimmune rheumatic diseases

21. Antigenic drift and subtype interference shape A(H3N2) epidemic dynamics in the United States.

22. Antigenic drift and subtype interference shape A(H3N2) epidemic dynamics in the United States

23. Combined analyses of within-host SARS-CoV-2 viral kinetics and information on past exposures to the virus in a human cohort identifies intrinsic differences of Omicron and Delta variants

24. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses

25. Combined analyses of within-host SARS-CoV-2 viral kinetics and information on past exposures to the virus in a human cohort identifies intrinsic differences of Omicron and Delta variants

27. SARS-CoV-2 mucosal neutralising immunity after vaccination

28. 34 COVID-19 caused by either Omicron sub-variants or Delta in non-hospitalised adults associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history

29. 33 Fourth dose bivalent mRNA vaccines containing BA.1 significantly augment neutralising antibody titres against SARS-COV-2 Omicron sub-lineages XBB and BQ.1.1 in healthy adults

30. Comparison of Serologic Assays for Middle East Respiratory Syndrome Coronavirus

31. The neuraminidase of A(H3N2) influenza viruses circulating since 2016 is antigenically distinct from the A/Hong Kong/4801/2014 vaccine strain

32. Antigenic drift and subtype interference shape A(H3N2) epidemic dynamics in the United States

35. COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history.

37. Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection

38. Dichotomy of neutralizing antibody, B cell and T cell responses to SARS-CoV-2 vaccination and protection in healthy adults

39. Within-host SARS-CoV-2 viral kinetics informed by complex life course exposures reveals different intrinsic properties of Omicron and Delta variants

40. Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer

42. A case of swine influenza A(H1N2)v in England, November 2023.

43. WHO's Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed

44. Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer

47. Bertran de Born and Raimon de Planell.

48. SARS-CoV-2 S2–targeted vaccination elicits broadly neutralizing antibodies

49. Non-hospitalised, vaccinated adults with COVID-19 caused by Omicron BA.1 and BA.2 present with changing symptom profiles compared to those with Delta despite similar viral kinetics

50. Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer

Catalog

Books, media, physical & digital resources